Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients
This study provides a robust framework for drug repurposing and novel drug discovery in SCD, particularly tailored to the Saudi population. The findings underscore the potential of leveraging genomic data to identify targeted therapies, offering a pathway to more personalized and effective treatments for SCD patients. Future clinical trials are essential to validate these findings and translate them into clinical practice.
Authors
- Imadul Islam (ORCID: https://orcid.org/0000-0003-3855-5354)
- Mohammed A. AlAwadh (ORCID: https://orcid.org/0000-0002-1126-5886)
- Mohammad A. Alshabeeb (ORCID: https://orcid.org/0000-0002-8885-6254)
- Suad Alshammari
- Dayanjan S. Wijesinghe (ORCID: https://orcid.org/0000-0002-2124-5109)
- Khalifa Alrajeh (ORCID: https://orcid.org/0000-0003-4406-1473)
- Ali Alghubayshi
- Mona Alkhairi
- Ahmed Alaskar
Institutions
- Northern Border University (SA)
- Virginia Commonwealth University (US)
- King Abdulaziz University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- University of Ha'il (SA)
- King Abdullah International Medical Research Center (SA)
- National Guard Health Affairs (SA)
- King Faisal University (SA)
Publication Details
- Journal
- Frontiers in Bioinformatics
- Published
- 2025-12-02
- DOI
- https://doi.org/10.3389/fbinf.2025.1671626
- Citations
- 1
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Virginia Commonwealth University
- King Abdullah International Medical Research Center